Israel - Ibrani - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - טבליות מצופות פילם - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor

Israel - Ibrani - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - טבליות מצופות פילם - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor

Israel - Ibrani - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - טבליות מצופות פילם - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor

Israel - Ibrani - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - טבליות מצופות פילם - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor

Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - pirfenidone - קפסולה קשיחה - pirfenidone 267 mg - pirfenidone

Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - pirfenidone - קפסולה קשיחה - pirfenidone 267 mg - pirfenidone

Israel - Ibrani - Ministry of Health

megapharm ltd - potassium sodium hydrogen citrate 2.427 g / 2.5 g - granules - potassium citrate - to dissolve uric acid stones in the urinary tract. prevention of further stone formation.

Israel - Ibrani - Ministry of Health

sanofi - aventis israel ltd - clopidogrel as hydrogen sulfate 300 mg - film coated tablets - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

Israel - Ibrani - Ministry of Health

inovamed ltd - rivastigmine as hydrogen tartrate 1.5 mg - capsules - rivastigmine - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia associated with parkinson's disease.

Israel - Ibrani - Ministry of Health

megapharm ltd - cholic acid - קפסולה קשיחה - cholic acid 250 mg - cholic acid